Horizon Europe
Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
17:00 Brussels time
Last verified:
Details
| Funder | Horizon Europe |
| Budget | €7M–€8M per grant (total budget €22,186,000) |
| Deadline | 15 September 2026 |
| Consortium | Required — minimum 3 entities from 3 EU member states |
| Application | Single-stage |
| Frequency | One-off |
Eligibility & scope
Supports randomised or cluster-randomised academic investigator-initiated pragmatic clinical trials for patients with refractory cancers, evaluating effectiveness of immunotherapeutic interventions in real-world settings. Proposals must include diverse stakeholders, disaggregate data by sex/gender/age, and engage patients in defining endpoints. Applicants should build on Knowledge Centre on Cancer resources and join the EU Cancer Mission 'Diagnosis and Treatment' cluster.
Related on Grantsby
- Horizon Europe writing tips & FAQ
Evaluation criteria, proposal structure, common mistakes.
More from Horizon Europe
Microbiome for early cancer prediction before the onset of disease
Deadline: 15 Sept 2026Around €15MVirtual Human Twin (VHT) Models for Cancer Research (HORIZON-MISS-2026-02-CANCER-01)
Deadline: 15 Sept 2026€8M–€9M per grant (total budget €35M, ~4 grants)Horizon-Miss-2026-02-Cancer-03 (Cancer Mission Ria)
Deadline: 15 Sept 2026€7M–€8M per grant (total budget €22.186M)Horizon-Miss-2026-02-Cancer-04 (Cancer Mission Ria)
Deadline: 15 Sept 2026Around €5M per grant (total budget €15M)HORIZON-MISS-2026-02-CANCER-05 (Cancer Mission Innovation Action)
Deadline: 15 Sept 2026Around €7M per grant (total budget €7M)
Does this grant match your research?
Sign up free to get a personalised match score and weekly alerts for grants like this.
Get started free